- Home
- KBR vs LEGN Comparison
KBR vs LEGN Comparison
Compare KBR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBR
- LEGN
- Stock Information
- Founded
- KBR 1901
- LEGN 2014
- Country
- KBR United States
- LEGN United States
- Employees
- KBR N/A
- LEGN N/A
- Industry
- KBR Military/Government/Technical
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- KBR Industrials
- LEGN Health Care
- Exchange
- KBR Nasdaq
- LEGN Nasdaq
- Market Cap
- KBR 6.4B
- LEGN 6.7B
- IPO Year
- KBR 2006
- LEGN 2020
- Fundamental
- Price
- KBR $49.38
- LEGN $35.16
- Analyst Decision
- KBR Buy
- LEGN Strong Buy
- Analyst Count
- KBR 8
- LEGN 12
- Target Price
- KBR $60.29
- LEGN $73.36
- AVG Volume (30 Days)
- KBR 1.0M
- LEGN 1.1M
- Earning Date
- KBR 10-22-2025
- LEGN 11-11-2025
- Dividend Yield
- KBR 1.35%
- LEGN N/A
- EPS Growth
- KBR 86.03
- LEGN N/A
- EPS
- KBR 2.75
- LEGN N/A
- Revenue
- KBR $8,047,000,000.00
- LEGN $796,838,000.00
- Revenue This Year
- KBR $4.80
- LEGN $70.75
- Revenue Next Year
- KBR $6.24
- LEGN $52.47
- P/E Ratio
- KBR $16.13
- LEGN N/A
- Revenue Growth
- KBR 12.31
- LEGN 74.75
- 52 Week Low
- KBR $43.89
- LEGN $27.34
- 52 Week High
- KBR $72.60
- LEGN $51.77
- Technical
- Relative Strength Index (RSI)
- KBR 49.71
- LEGN 49.17
- Support Level
- KBR $48.16
- LEGN $32.70
- Resistance Level
- KBR $49.81
- LEGN $34.71
- Average True Range (ATR)
- KBR 0.94
- LEGN 1.24
- MACD
- KBR -0.18
- LEGN 0.15
- Stochastic Oscillator
- KBR 37.20
- LEGN 65.13
About KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is a global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: mission technology solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 34,000 people. The firm generated $7.7 billion in revenue in 2024.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.